Navigation Links
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
Date:7/14/2008

MOUNTAIN VIEW, Calif., July 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine.

MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In the company's prior Phase 2 efficacy study, MAP0004 provided pain relief in as fast as 10 minutes, with relief sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia, the other key measurements in treating migraine.

This randomized, double-blind, placebo-controlled Phase 3 trial is designed to evaluate the efficacy and safety of MAP0004 in treating acute migraine. The primary efficacy endpoints will be pain relief, and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. MAP will also evaluate earliest onset of pain relief and sustained relief to 24 and 48 hours. The multi-center efficacy trial will include approximately 850 patients, who will also be followed for 12 months in an open-label study to confirm long-term safety.

"We believe that MAP0004 has the potential to be a first-line therapy for migraine patients," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Based on our initial clinical studies, we believe that MAP0004 offers an alternative to triptans that may provide patients with the benefits of rapid onset and long-lasting pain relief, in an easy-to-use, non-invasive, at-home therapy. In our Phase 2 trials, MAP0004 was well tolerated with no effect on pulmonary function, including in asthmatic subjects."

The therapeutic agent
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BEIJING , Dec. 24, 2014  The International Trade ... by ResMed (RMD) against BMC Medical. In a notice issued ... and found that ResMed,s patent on its humidifier was invalid. ... decision a "monumental win". "We are very excited with the ... the position that we have taken since the very beginning ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced ... medical device manufacturer BMC Medical Co., Ltd. ... listed below infringe ResMed,s patents, and entered an order prohibiting ... the United States : , iVolve ... Willow nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... VIEW, Calif., Sept. 16 Based on its recent ... market, Frost & Sullivan recognizes Accelrys, Inc., with the ... Product Innovation of the Year. The company has merited ... a solution that provides, for the first time, a ...
... (LIG) (Pink Sheets: LIGA ), a Dallas-based ... cleaner and disinfectant for the masks of CPAP (continuous ... for patients suffering from sleep apnea. The ... by Jones Products Company, LLC, which is 51% owned ...
Cached Medicine Technology:Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 2Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 3Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 4LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner 2LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner 3
(Date:12/26/2014)... Angeles, CA (PRWEB) December 26, 2014 ... power score of 3.1 out of 5. This score ... a low level of product specialization, low switching costs ... power is reduced by the low availability of substitutes ... the world price of steel and aluminum, key inputs ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... Phoenix, AZ (PRWEB) December 26, 2014 ... dependable source for the best in heating, cooling ... demand for 24 hour emergency services in 2014 ... customers alike know that Arizona is known for ... contractor company that understands the intricacies and details ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... N.J., Dec. 3 Covance Inc. (NYSE:,CVD), a ... leading,humanitarian organization, announced today that they are partnering ... for,Orphans and Vulnerable Children in Rwanda. Covance will ... day care centers for,children ages two to four ...
... protect cells from the powerful, common chemotherapeutic agent doxorubicin ... the drug also can destroy the heart., We found ... cell survival in the face of doxorubicin, says Dr. ... Georgia Cancer Center. At the moment you start inactivating ...
... debate , MONDAY, Dec. 3 (HealthDay News) -- There,s ... the risk of developing multiple sclerosis (MS) in childhood, a ... investigated a possible association between the hepatitis B vaccine and ... short- or long-term risk of MS. However, the studies ...
... HARBOR, N.Y. (Mon., Dec. 3, 2007) Two ... early embryogenesis are featured in this months release of ... which are freely accessible online ( www.cshprotocols.org ), describe ... These cell-tagging techniques, combined with sophisticated imaging methods, ...
... As momentum continues to,build on the issue of ... the Pharmaceutical Care Management Association,(PCMA) today announced a ... Ph.D., Sc.D., Last year, Dr. Bootman co-chaired ... all physicians begin using e-prescribing by,2010 to help ...
... and HUNTSVILLE, Ala., Dec. 3 Operon,Biotechnologies, Eurofins ... the,Eurofins Genomics network - announced today that they ... a new worldwide leader in the competitive,custom oligonucleotide ... state of,the art high-throughput production facilities in all ...
Cached Medicine News:Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 2Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 3Health News:Genes identified that protect against heart damage from chemotherapy 2Health News:No Link Between Hepatitis B Shot, MS: Study 2Health News:Cold Spring Harbor Protocols features innovative methods for embryology research 2Health News:MWG and Operon Are Joining Forces 2
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Inquire...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
Medicine Products: